126 related articles for article (PubMed ID: 22368233)
1. Strong antiviral activity of the new l-hydroxycytidine derivative, l-Hyd4FC, in HBV-infected human chimeric uPA/SCID mice.
Volz T; Lütgehetmann M; Allweiss L; Warlich M; Bierwolf J; Pollok JM; Petersen J; Matthes E; Dandri M
Antivir Ther; 2012; 17(4):623-31. PubMed ID: 22368233
[TBL] [Abstract][Full Text] [Related]
2. The hepatitis B virus-trimera mouse: a model for human HBV infection and evaluation of anti-HBV therapeutic agents.
Ilan E; Burakova T; Dagan S; Nussbaum O; Lubin I; Eren R; Ben-Moshe O; Arazi J; Berr S; Neville L; Yuen L; Mansour TS; Gillard J; Eid A; Jurim O; Shouval D; Reisner Y; Galun E
Hepatology; 1999 Feb; 29(2):553-62. PubMed ID: 9918935
[TBL] [Abstract][Full Text] [Related]
3. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation.
Lütgehetmann M; Mancke LV; Volz T; Helbig M; Allweiss L; Bornscheuer T; Pollok JM; Lohse AW; Petersen J; Urban S; Dandri M
Hepatology; 2012 Mar; 55(3):685-94. PubMed ID: 22031488
[TBL] [Abstract][Full Text] [Related]
4. In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice.
Lutgehetmann M; Volz T; Köpke A; Broja T; Tigges E; Lohse AW; Fuchs E; Murray JM; Petersen J; Dandri M
Hepatology; 2010 Jul; 52(1):16-24. PubMed ID: 20578126
[TBL] [Abstract][Full Text] [Related]
5. Antiviral activity of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus.
Le Guerhier F; Pichoud C; Jamard C; Guerret S; Chevallier M; Peyrol S; Hantz O; King I; Trépo C; Cheng YC; Zoulim F
Antimicrob Agents Chemother; 2001 Apr; 45(4):1065-77. PubMed ID: 11257017
[TBL] [Abstract][Full Text] [Related]
6. The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV.
Meuleman P; Leroux-Roels G
Antiviral Res; 2008 Dec; 80(3):231-8. PubMed ID: 18706933
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection.
Klumpp K; Shimada T; Allweiss L; Volz T; Lütgehetmann M; Hartman G; Flores OA; Lam AM; Dandri M
Gastroenterology; 2018 Feb; 154(3):652-662.e8. PubMed ID: 29079518
[TBL] [Abstract][Full Text] [Related]
8. Chronic infection with hepatitis B viruses and antiviral drug evaluation in uPA mice after liver repopulation with tupaia hepatocytes.
Dandri M; Burda MR; Zuckerman DM; Wursthorn K; Matschl U; Pollok JM; Rogiers X; Gocht A; Köck J; Blum HE; von Weizsäcker F; Petersen J
J Hepatol; 2005 Jan; 42(1):54-60. PubMed ID: 15629507
[TBL] [Abstract][Full Text] [Related]
9. A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections.
Kosaka K; Hiraga N; Imamura M; Yoshimi S; Murakami E; Nakahara T; Honda Y; Ono A; Kawaoka T; Tsuge M; Abe H; Hayes CN; Miki D; Aikata H; Ochi H; Ishida Y; Tateno C; Yoshizato K; Sasaki T; Chayama K
Biochem Biophys Res Commun; 2013 Nov; 441(1):230-5. PubMed ID: 24140055
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of L-Fd4C and related nucleoside analogs as promising antiviral agents.
Chen SH
Curr Med Chem; 2002 May; 9(9):899-912. PubMed ID: 11966452
[TBL] [Abstract][Full Text] [Related]
11. Virion half-life in chronic hepatitis B infection is strongly correlated with levels of viremia.
Dandri M; Murray JM; Lutgehetmann M; Volz T; Lohse AW; Petersen J
Hepatology; 2008 Oct; 48(4):1079-86. PubMed ID: 18697217
[TBL] [Abstract][Full Text] [Related]
12. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels.
Wong DK; Yuen MF; Ngai VW; Fung J; Lai CL
Antivir Ther; 2006; 11(7):909-16. PubMed ID: 17302253
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model.
Le Guerhier F; Pichoud C; Guerret S; Chevallier M; Jamard C; Hantz O; Li XY; Chen SH; King I; Trépo C; Cheng YC; Zoulim F
Antimicrob Agents Chemother; 2000 Jan; 44(1):111-22. PubMed ID: 10602731
[TBL] [Abstract][Full Text] [Related]
14. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus.
Volz T; Allweiss L; Ben MBarek M; Warlich M; Lohse AW; Pollok JM; Alexandrov A; Urban S; Petersen J; Lütgehetmann M; Dandri M
J Hepatol; 2013 May; 58(5):861-7. PubMed ID: 23246506
[TBL] [Abstract][Full Text] [Related]
15. Animal models for the study of HBV infection and the evaluation of new anti-HBV strategies.
Zoulim F; Berthillon P; Guerhier FL; Seigneres B; Germon S; Pichoud C; Cheng YC; Trepo C
J Gastroenterol Hepatol; 2002 Dec; 17 Suppl():S460-3. PubMed ID: 12534778
[TBL] [Abstract][Full Text] [Related]
16. Direct cytopathic effects of particular hepatitis B virus genotypes in severe combined immunodeficiency transgenic with urokinase-type plasminogen activator mouse with human hepatocytes.
Sugiyama M; Tanaka Y; Kurbanov F; Maruyama I; Shimada T; Takahashi S; Shirai T; Hino K; Sakaida I; Mizokami M
Gastroenterology; 2009 Feb; 136(2):652-62.e3. PubMed ID: 19041311
[TBL] [Abstract][Full Text] [Related]
17. Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse.
Vanwolleghem T; Meuleman P; Libbrecht L; Roskams T; De Vos R; Leroux-Roels G
Gastroenterology; 2007 Oct; 133(4):1144-55. PubMed ID: 17919490
[TBL] [Abstract][Full Text] [Related]
18. A preliminary trial of lamivudine for chronic hepatitis B infection.
Dienstag JL; Perrillo RP; Schiff ER; Bartholomew M; Vicary C; Rubin M
N Engl J Med; 1995 Dec; 333(25):1657-61. PubMed ID: 7477217
[TBL] [Abstract][Full Text] [Related]
19. A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.
Mazur W; Król F; Cianciara J; Nazzal K; Gładysz A; Juszczyk J; Bolewska B; Adamek J; Czajka B; Swietek K; Kryczka W; Gonciarz Z
Med Sci Monit; 2002 Apr; 8(4):CR257-62. PubMed ID: 11951067
[TBL] [Abstract][Full Text] [Related]
20. Human hepatocytes secrete soluble CD14, a process not directly influenced by HBV and HCV infection.
Meuleman P; Steyaert S; Libbrecht L; Couvent S; Van Houtte F; Clinckspoor F; de Hemptinne B; Roskams T; Vanlandschoot P; Leroux-Roels G
Clin Chim Acta; 2006 Apr; 366(1-2):156-62. PubMed ID: 16253217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
